Download PDFPDF

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Age as a risk factor for hemorrhage in aspirin users

    April 3, 2001

    To the Editor:

    It seems that there is a potential flaw in the analysis by Sanmuganathan, et al (1), of the relative risk benefit ratio in the use of aspirin for the primary prevention of coronary artery disease. The coronary risks are calculated using tables in which age is a major determinant, but the risks of a bleeding complication are averaged over all ages. Since bleeding complicat...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Re: Age as a risk factor for hemorrhage in aspirin users
    • PS Sanmuganathan
    • Other Contributors:
      • "P Ghahramani, PR Jackson, EJ Wallis, LE Ramsay"

    Dear Editor,

    Dr Levitt has raised a valuable point that the risk benefit relationship of aspirin may vary with age as well as CHD risk and it is worth re-evaluating the conclusions made in our paper [1].

    He has however misunderstood the way in which we calculated benefit from aspirin treatment. Because haemorrhagic strokes were not always reported separately they had to be included in cardiovascular e...

    Show More
    Conflict of Interest:
    None declared.